Back to News
M&A

Merck Expands Oncology Pipeline With ArQule

|
Published: June 22nd, 2020
The biopharmaceutical giant is paying a 107% premium for the target, which focuses on therapies for treating cancer and rare diseases.

Biopharmaceutical giant Merck & Co. Inc. (MRK) said Monday, Dec. 9, it is buying ArQule Inc. (ARQL) for $20 a share or about $2.7 billion in a move that broadens its pipeline in oncology.

The price tag marks a 107% premium over ArQule’s closing share price on Friday.

Burlington, Mass.-based ArQule focuses on therapies for treating cancer and rare diseases. The company’s lead investigational candidate, ARQ 531, is an inhibitor of an enzyme known as Bruton’s tyrosine kinase. ARQ 531 is in a Phase 2 dose expansion study to treat B-cell malignancies.

The deal announcement came on the same day that ArQule unveiled final results from a Phase 1 study of ARQ 531 at the American Society of Hematology 2019 Annual Meeting & Exposition in Orlando, Fla.

This Content is Only for The Deal Subscribers

The Deal provides actionable, intraday coverage of mergers, acquisitions and all other changes in corporate control to institutional investors, private equity, hedge funds and the firms that serve them.

If you’re already a subscriber, log in to view this article here.

More From M&A

M&A

Review: Thinking Through Contract Drafting

By David Marcus
|
Published: March 25th, 2024
In their new book 'Deals,' Stanford’s Mike Klausner and Harvard’s Guhan Subramanian offer a theoretical framework for thinking about how to write corporate contracts.
M&A

Drinks With The Deal: Cadence's Stone on Marine Corps Lessons

By David Marcus
|
Published: February 29th, 2024
On this week’s episode of Drinks With The Deal, Ryan Stone, a corporate development professional at Cadence Design Systems, discusses how an early stint in the Marine Corps helped shape his career.